×

Immunomic Therapeutics Names Louise Peltier as Vice President, Regulatory Affairs

HERSHEY, Pa. and ROCKVILLE, Md., May 6, 2015 (GLOBE NEWSWIRE) -- Immunomic Therapeutics, Inc., ("ITI") a privately-held biotechnology company developing vaccines based on its proprietary LAMP technology, today announces it has appointed Louise Peltier as its new vice president of regulatory affairs beginning May 4, 2015.

"Louise has experience both in-house and consulting and understands the ever-evolving regulatory environment," said William Hearl, Ph.D., CEO of ITI. "As ITI continues to develop as a company and we continue to take our products through the regulatory process, we look forward to success under Louise's guidance."

With more than 30 years of experience in the regulatory space, Ms. Peltier has worked both as a consultant and in-house at such well-known life sciences companies as PharmAthene, Northwest Biotherapeutics, Caris Life Sciences, Guilford Pharmaceuticals and Centocor where she oversaw countless regulatory filings, meetings and pharmacovigilance, in both the US and abroad.

About Immunomic Therapeutics, Inc.

Immunomic Therapeutics, Inc. (ITI) is a Hershey, PA-based, privately held, clinical stage biotechnology company developing vaccines based on the LAMP technology platform, which was exclusively licensed from Johns Hopkins University. The LAMP-vax vaccine platform aims to increase the immune response to nucleic acid vaccines and simplify vaccine design and delivery for safer, more cost-effective therapies. ITI's LAMP constructs have been validated in human clinical trials for cancer and have been studied in areas including allergy and infectious disease, while internally ITI is focused on developing allergy therapies. Currently, the company is pursuing three main allergy programs:

  • ASP 4070 (Formerly known as JRC-LAMP-Vax) - Japanese Red Cedar Vaccine - An innovative potential solution for the over 35 million sufferers of Japanese red cedar pollinosis - Phase I, currently partnered with Astellas Pharma;
    • An analogous vaccine formulation will be developed as a vaccine to treat Mountain Cedar in the US.
  • ARA-LAMP-Vax Peanut Allergy Vaccine - A therapeutic vaccine in development, with a goal of mitigating peanut allergy - Beginning Phase I in late 2015/early 2016;
  • Multi Allergen Vaccines (Product Concepts) - Allergy vaccine formulation concepts that would aim to address the major categories of allergies of concern Worldwide - Under study & development.

For more information about ITI and LAMP Technology, please visit www.immunomix.com.

CONTACT: Jules Abraham JQA Partners, Inc. jabraham@jqaparnters.com (917) 885-7378 Sia Anagnostou Immunomic Therapeutics, Inc sia@immunomix.com http://www.immunomix.com (717) 327-1822Source:Immunomic Therapeutics, Inc.